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Abstract
Background: Hashimoto’s encephalitis (HE) is a rare neurological complication of Hashimoto’s thyroiditis (HT), while
limbic encephalitis (LE) is an autoimmune inflammatory disorder frequently associated with anti-neuronal
antibodies. The glutamate receptor α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) is
important for synaptic transmission, memory, and learning. The etiology of HE remains unclear. We present a case
of HE with antibodies to AMPAR2 both in the serum and cerebrospinal fluid.
Case presentation: The patient presented with progressive memory loss and subsequently went into a coma.
Magnetic resonance imaging revealed temporal lobe and hippocampal lesions, while the electrocardiogram showed
paroxysmal delta waves. Elevated serum levels of antibodies against thyroid globulin, thyroid peroxidase, and thyroid
stimulating receptor were also noted. Ultrasonography showed enlargement of the thyroid gland. Therefore, the
diagnosis was established as HE. Both the CSF and serum samples of the patient tested positive for antibodies to the
cell-surface antigen AMPAR2. Intravenous injection of immunoglobulin followed by dexamethasone treatment resulted
in recovery from the coma. Follow-up examination three months later showed some improvement of memory. To our
knowledge, this is the first report on the detection of AMPAR2 antibodies in HE.
Conclusions: Our findings suggest that antibodies to AMPAR2 may be involved in the pathogenesis of HE. Elevated
levels of thyroid antibodies possibly cause immune dysfunction, leading to the production of anti-AMPAR2 antibodies
that are detrimental to the neurons. We believe that encephalitis patients with thyroid abnormalities should undergo
screening for anti-neuronal antibodies, and early immune therapy may improve prognosis.
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Background
Hashimoto’s thyroiditis (HT) is the most common type
of autoimmune thyroid disease (AITD); it is character-
ized by the presence of high titers of anti-thyroid anti-
bodies in the blood [1]. The neurological complication
of HT, namely, Hashimoto’s encephalitis (HE,) was first
reported in the 1960’s by Brain et al. [2]. The clinical
presentations of HE are diverse, ranging from focal signs
similar to those manifested in stroke-like events to those
reflecting diffuse panencephalitis, such as altered cogni-
tion and psychosis [3, 4].
Limbic encephalitis (LE) is an autoimmune inflamma-
tory disorder of the limbic system, involving the medial
temporal lobe, amygdala, and cingulate gyri. Clinically, it
is clinically manifested by short-term memory deficit,
psychosis, and seizures [5]. Recent studies have suggested
that the pathogenesis of LE is mediated by anti-neuronal
antibodies, including antibodies to both intra-neuronal
and cell-surface antigens. Intra-neuronal antigens are usu-
ally paraneoplastic, while cell-surface antigens are thought
to be immune-mediated [5–7]. The glutamate receptor α-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid re-
ceptor (AMPAR) is a cell-surface ionotropic receptor that
plays important roles in synaptic transmission, memory,
and learning [8]. Anti-AMPAR encephalitis was first re-
ported in 2009 in a cohort study of ten patients [9]. Expos-
ure of neurons to the antibodies causes a significant
decrease in the total amount of AMPAR cluster and syn-
aptic locations of GluA1- and GluA2-containing AMPARs
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[10], which demonstrates the pathogenic effect of anti-
AMPAR antibodies.
Even to date, the pathogenesis of HE is largely unclear
and widely debated. Several mechanisms, such as vascu-
litis, cerebral hypoperfusion and cerebral tissue specific
autoimmunity, have been postulated thus far. In this
paper, we present a case of HE with evidence of anti-
bodies against AMPAR2 positive both in the serum and
cerebrospinal fluid (CSF) [4].
Case presentation
A 54-year-old previously healthy woman was admitted
to our hospital for progressive cognitive decline and
memory loss since 5 days. The patient’s symptoms
started with the inability to remember the names and
the functions of the condiments on the first day. The
next day, the patient had difficulty in recollecting the
names of her close relatives, in addition to dizziness and
fatigue. At the time of admission, the patient was con-
scious, but confused. History taking revealed no fever,
headache, or significant weight loss during the past three
months, and no family history of auto-immune diseases.
On further clinical examination, long-term and short-
term memory, the ability of calculation, as well as tem-
poral and spatial perception were found to be impaired.
No other neurological signs were present, expect for a
positive Chaddok sign on the left side.
The first magnetic resonance image (MRI) obtained at
the local hospital showed normal findings. The second
MRI repeated on the next day at our hospital revealed
patchy lesions in the left temporal lobe and hippocampal
area. The lesions showed high signal intensity on T1-
and T2-weighted imaging and high signal intensity on
the fluid-attenuated inversion recovery (FLAIR) se-
quence (Fig 1a-c). Electrocardiography (EEG) revealed
paroxysmal delta waves in the left temporal lobe. Ultra-
sonographic examination showed enlargement of the
thyroid gland (left thyroid lobe: 16 mm × 6 mm, and
right thyroid lobe: 15 mm × 16 mm × 43 mm), with ir-
regular echogenicity. However, ultrasonography examin-
ation of the abdominal organs, including the liver,
kidney, pancreas and uterus, as well as other organs,
Fig. 1 a-d. Axonal magnetic resonance imaging (MRI) scans revealed patchy lesions in the left temporal lobe and hippocampus. The lesions were
represented by areas of low signal intensity on T1-weighted imaging (a) and high signal intensity on T2-weighted imaging (b) sequence and high
signal intensity on the fluid-attenuated inversion recovery (FLAIR) sequence (c). Anti-AMPAR2 antibodies in the serum of the patient was positive,
as tested by CBA method (d)
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such as mammary glands, did not reveal any abnormal-
ity. Pulmonary computed tomography (CT) scan was
negative for neoplasia.
The findings of routine blood tests were normal, ex-
cept for slightly low levels of sodium (133.9, normal
range: 137–147 mmol/L) and chloride (97, normal
range: 99–110 mmol/L). The screening assay for viral
infection showed elevated levels of antibodies against
herpes simplex virus I (HSV I) (8.023 S/CO, normal
range: <1.00 S/CO), rubella virus (0.927 S/CO, normal
range: <1.00 S/CO), and cytomegalovirus (CMV)
(6.332 S/CO, normal range, normal range: <1.00 S/
CO) in the serum but not in the CSF. The results of
the lumbar puncture test showed increased intracra-
nial pressure (230 mm H2O; normal range: 70–
180 mm H2O). Routine analysis of the CSF showed in-
creased concentration of protein (0.50 g/L, normal
range 0.15–0.45 g/L) and elevated white blood cell
count (63 × 106/L, normal range: 0–8 × 106/L), with
89% lymphocytes, 7% eosinophils, and 4% monocytes.
The CSF was negative for oligoclonal bands. Further,
the levels of the immunoglobulin (Ig) G were also
found to be slightly increased (49.1 mg/L; normal
range: 0–34.0 mg/L) in the CSF. The results of the
autoimmune encephalitis test using cell-based assay
(CBA) for antibodies against AMPAR2 were positive
for both the serum and CSF (Fig 1d), but negative for
other antibodies, including NMDA-R, CASPR2,
AMPA1-R, and LGI1. Screening tests were also nega-
tive for paraneoplastic markers, including Hu, Yo, Ri,
paraneoplastic Ma2 (PNMA2), CV2/collapsing re-
sponse mediator 5 (CRMP5), and amphiphysin. Add-
itionally, tests for tuberculosis were negative. Thyroid
function-related tests showed slightly lower levels of
thyroid stimulating hormones (TSH) (0.26 mIU/L;
normal range: 0.27–4.2 mIU/L), while the serum levels
of free T3 and T4 were within the normal range.
Levels of the antibodies against the thyroid globulin
(TG) (2006 IU/ml, normal range <115 IU/ml), thyroid
peroxidase (TPO) (276.9 IU/ml, normal range <35 IU/
ml), and thyroid stimulating receptor (TSHR)
(13.6 IU/ml, normal range 0.3-1.75 IU/ml) were found
to be elevated. Tests for antibodies against and antigen
of hepatitis B and C virus were all negative. Antibody
tests for human immunodeficiency virus (HIV) and
syphilis were also negative, as were the screening tests
for the tumor biomarkers. The results of routine urine
analysis and tests for liver and kidney function were
normal. The blood levels of lipids and glucose were
also within the normal range. The erythrocyte sedi-
mentation rate and levels of the C-reactive proteins
were also within the normal range.
On the basis of the results of the preliminary physical
examination and the laboratory tests conducted on the
day of admission, viral encephalitis was suspected. Ac-
cordingly, the patient was treated with the anti-virus
drug acyclovir. However, there was no significant relief
in the patient’s symptoms. Four days later, the patient’s
conditions worsened and the patient went into a coma;
therefore, she was shifted to the intensive care unit.
There, anti-AMPAR2 antibodies were detected in the
serum and CSF, and accordingly, the patient was treated
with intravenous injection of immunoglobulin (IVIG) for
3 days followed by dexamethasone. Once the IVIG treat-
ment was initiated, the patient recovered from coma.
Follow-up examination after 3 months showed that her
memory function had improved to some extent, but not
completely restored.
Discussion
In this paper, we presented a case of HE in which both
serum and CSF were positive for antibodies to AMPAR2.
HE is a rare neurological complication of HT, and ap-
proximately, one-third of HE cases occur in the euthyr-
oid state of HT [11]. Although HE has been a known
clinical entity since 50 years, its etiology is still not fully
understood.
Our patient had progressive memory loss and eventually
slipped into a coma. MRI scan showed lesions in the tem-
poral lobe and hippocampus, while the EEG showed parox-
ysmal delta waves. Furthermore, the patient had elevated
serum levels of antibodies to TG, TPO, and TSHR. In the
light of these findings, the diagnosis was established as HE.
High levels of anti-thyroid antibodies have been previously
reported in the CSF of HE patients [12].
Moreover, anti-thyroid antibodies have been showed
to bind to astrocytes [13], suggesting a direct pathogenic
link between the two. However, the levels of anti-thyroid
antibodies do not correlate with the severity of the clin-
ical syndrome, and immunotherapy does not always re-
duce the levels of anti-thyroid antibodies despite reliving
the clinical symptoms [14]; these findings suggest that
there are more mechanisms, hitherto undiscovered, may
be involved in the pathogenesis of HE. It has been sug-
gested that anti-thyroid antibodies could serve as
markers for autoimmune disease in the brain and anti-
neuronal auto-antibodies may exist in HE. Oide et al.
showed that serum of HE patients contained an anti-
neuronal autoantibody that reacted with a 36-kDa anti-
genic protein from human cerebral cortex [15]. More-
over, the CSF of HE patients has been shown to test
positive for other anti-neuronal auto-antibodies against
enzymes expressed by neurons [16].
The antibodies to the cell surface antigen AMPAR2
were found positive both in the CSF and in the serum of
this patient. To our knowledge, this is the first report on
the detection of AMPAR2 antibodies in HE patients.
Since the first report of AMPAR encephalitis in 2009, no
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more than 50 cases have been reported thus far [17].
One peculiar feature of this case is that the clinical pres-
entation in this case is also consistent with the diagnosis
of AMPAR2 LE. More than half of the cases of AMPAR
encephalitis show evidence of coexistent tumor [17, 18].
Therefore, to rule out coexistent neoplasia, we per-
formed ultrasonography of the abdominal organs and
mammary glands in addition to pulmonary CT. How-
ever, no evidence of tumors was obtained in these scans.
Moreover, screening for tumor markers and paraneo-
plastic auto-antibodies also did not yield any significant
findings. Thus, caner was ruled out in this patient. In
the light of our experience in this case, we speculate that
the elevated levels of anti-thyroid antibodies may have
caused immune dysfunction in the brain; this may have
triggered the production of AMPAR2 antibodies, which,
in turn, have a detrimental effect on neurons. It would
be worthwhile to further investigate whether anti-
thyroid antibodies have a causative relationship with
the\production of AMPAR2 antibodies.
Vasculitis is another leading theory used to explain the
etiology of HE. An autopsy study in a 77-year-old female
patient showed infiltration of inflammatory CD3-positive
T-lymphocytes in the brain stem, cerebellum, and cor-
tex. In line with this hypothesis, increased concentra-
tions of protein were found in the CSF of our patient,
indicating the disruption of the blood brain barrier
(BBB). Furthermore, increases were noted in the number
of monocytes and eosinophils in our patient. Increase of
the inflammatory cells in the CSF can produce inflam-
matory cytokines, which can cause damage to the
neurons.
The patient’s symptoms improved after initiation of
IVIG treatment. Immunotherapy should be considered
as the first-line-treatment for both HE and LE, and most
of the patients show immediate response to the treat-
ment, with reversal of the symptoms as well as MRI
changes. However, the persistence of the neurologic defi-
cits and eventual fatality may occur depending on the
severity of the disease and complication of other organs.
This patient’s memory deficits did not completely re-
cover despite administration of immunotherapy. There-
fore, IVIG or glucocorticoid treatment alone or their
combination is recommended as soon as the diagnosis is
established.
Conclusions
Our findings in this case support the role of inflammatory
autoimmunity in the pathogenesis of HE. Anti-thyroid
antibodies may cause dysregulation of the immune cells in
the brain, leading to the production of antibodies to
AMPAR2, which in turn are detrimental to neurons. Our
experience in this case also indicates that encephalitis pa-
tients with autoimmune thyroid disease should undergo
screening for anti-neuronal antibodies and receive early
immune therapy for a better prognosis.
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